NASDAQ:GOSS - Gossamer Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gossamer Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.16 -0.16 (-1.55 %) (As of 03/31/2020 01:06 PM ET) Add Compare Today's Range$9.92Now: $10.16▼$10.4450-Day Range$8.00MA: $12.39▼$15.4852-Week Range$7.52Now: $10.16▼$27.15Volume124,072 shsAverage Volume511,576 shsMarket Capitalization$674.01 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOSS Previous Symbol CUSIPN/A CIKN/A Webhttp://www.gossamerbio.com/ Phone858-922-0718Debt Debt-to-Equity Ratio0.11 Current Ratio11.09 Quick Ratio11.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book1.90Profitability EPS (Most Recent Fiscal Year)($3.29) Net Income$-180,310,000.00 Net MarginsN/A Return on Equity-43.11% Return on Assets-37.57%Miscellaneous Employees118 Outstanding Shares66,340,000Market Cap$674.01 million Next Earnings Date5/12/2020 (Estimated) OptionableNot Optionable Receive GOSS News and Ratings via Email Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GOSS Rates by TradingView Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions How has Gossamer Bio's stock been impacted by COVID-19 (Coronavirus)? Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GOSS stock has decreased by 4.1% and is now trading at $10.16. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Gossamer Bio? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gossamer Bio. When is Gossamer Bio's next earnings date? Gossamer Bio is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Gossamer Bio. How were Gossamer Bio's earnings last quarter? Gossamer Bio Inc (NASDAQ:GOSS) posted its quarterly earnings data on Tuesday, March, 24th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.03. View Gossamer Bio's earnings history. What price target have analysts set for GOSS? 5 brokers have issued 12-month price targets for Gossamer Bio's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Gossamer Bio's share price to reach $27.80 in the next twelve months. This suggests a possible upside of 173.6% from the stock's current price. View analysts' price targets for Gossamer Bio. Has Gossamer Bio been receiving favorable news coverage? News articles about GOSS stock have trended very positive recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gossamer Bio earned a news impact score of 3.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutGossamer Bio. Who are some of Gossamer Bio's key competitors? Some companies that are related to Gossamer Bio include Ultragenyx Pharmaceutical (RARE), PPD (SDGR), Amicus Therapeutics (FOLD), ArQule (ARQL), HUTCHISON CHINA/S (HCM), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Myokardia (MYOK), Axsome Therapeutics (AXSM), Deciphera Pharmaceuticals (DCPH), Alkermes (ALKS), Ra Pharmaceuticals (RARX), Taro Pharmaceutical Industries (TARO), Arena Pharmaceuticals (ARNA) and Allakos (ALLK). What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Tcr2 Therapeutics (TCRR), II-VI (IIVI), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Precision BioSciences (DTIL), Heron Therapeutics (HRTX), Akero Therapeutics (AKRO) and Crispr Therapeutics (CRSP). Who are Gossamer Bio's key executives? Gossamer Bio's management team includes the following people: Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)Mr. Bryan Giraudo, Chief Financial Officer (Age 43)Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)Dr. Jakob Dupont, Chief Medical Officer (Age 54) When did Gossamer Bio IPO? (GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. What is Gossamer Bio's stock symbol? Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS." How do I buy shares of Gossamer Bio? Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Gossamer Bio's stock price today? One share of GOSS stock can currently be purchased for approximately $10.16. How big of a company is Gossamer Bio? Gossamer Bio has a market capitalization of $674.01 million. The company earns $-180,310,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe. View additional information about Gossamer Bio. What is Gossamer Bio's official website? The official website for Gossamer Bio is http://www.gossamerbio.com/. How can I contact Gossamer Bio? Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718. MarketBeat Community Rating for Gossamer Bio (NASDAQ GOSS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 83 (Vote Outperform)Underperform Votes: 94 (Vote Underperform)Total Votes: 177MarketBeat's community ratings are surveys of what our community members think about Gossamer Bio and other stocks. Vote "Outperform" if you believe GOSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GOSS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: Hold Rating
